Adding trilaciclib to chemo-immunotherapy did not improve PFS in advanced urothelial cancer
RCT · Clin Genitourin Cancer · 2026-11-17. Number 4 in the UrologyWatch Top 5 for November 17, 2026.
In a randomized phase 2 trial of 92 patients with advanced urothelial carcinoma, adding trilaciclib to platinum chemotherapy plus avelumab maintenance showed modest myeloprotective effects but no improvement in progression-free survival (6.6 vs 6.1 months overall, HR 0.94).
Why it matters: Indicates trilaciclib added to standard first-line chemoimmunotherapy does not improve antitumor efficacy in advanced urothelial cancer.
Limitation: Phase 2 trial with modest sample size; higher complete response rate in a cisplatin subgroup was exploratory.
Source: Clin Genitourin Cancer · PubMed 43039758 · DOI 10.1016/j.clgc.2026.102692
Loading today's edition…